Daratumumab (Darzalex)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Anti-CD38 antibody, human monoclonal IgG1 kappa. Daratumumab binds to CD38 and causes apoptosis in CD38-expressing cells via Fc mediated cross-linking, complement-dependent cytotoxicity (CDC), antibody-dependent cell mediated cytotoxicity (ADCC), and antibody dependent cellular phagocytosis (ADCP). CD38 is present on the cell surface of multiple myeloma (MM), plasma leukemia, and natural killer (NK) cells.[1][2][3][4]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Code name: JNJ-54767414
  • Brand names: Darzalex, HuMax-CD38

References

  1. 1.0 1.1 1.2 1.3 Daratumumab (Darzalex) package insert
  2. Daratumumab (Darzalex) package insert (locally hosted backup)
  3. Daratumumab page at NCI Drug Dictionary
  4. Darzalex manufacturer's website
  5. Daratumumab (Darzalex) patient drug information (Chemocare)
  6. Daratumumab (Darzalex) patient drug information (UpToDate)